Naltrexone is under clinical development by Allodynic Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Naltrexone’s likelihood of approval (LoA) and phase transition for Psychiatric Disorders took place on 13 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Naltrexone Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Naltrexone overview
Naltrexone is under development for the treatment of postherpetic neuralgia, chronic low back pain, migraine, adjustment disorder (emotional pain). The drug candidate acts by targeting opioid receptors.
Quick View Naltrexone LOA Data
Report Segments |
|
Drug Name |
|
Administration Pathway | |
Therapeutic Areas |
|
Key Developers |
|
Highest Development Stage |
|